Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence for dupuytren's disease
3.2.1.2 Advancements in drug delivery technologies
3.2.1.3 Rising geriatric population
3.2.2 Industry pitfalls & challenges
3.2.2.1 High research and development cost
3.2.2.2 Potential side effects and complications
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.5.1 Core technologies
3.5.2 Adjacent technologies
3.6 Pricing analysis, 2023
3.6.1 By region
3.6.2 By key player
3.7 Future market trends
3.8 Pipeline analysis
3.9 Porter’s analysis
3.10 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Type I
5.3 Type II
5.4 Type III
Chapter 6 Market Estimates and Forecast, By Therapeutics, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Collagenase injection
6.3 Steroids
6.4 Immune-modulators
6.5 Other therapeutics
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Retail pharmacy
7.3 Hospital pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Europe
8.2.1 Germany
8.2.2 UK
8.2.3 France
8.2.4 Spain
8.2.5 Italy
8.2.6 Netherlands
8.2.7 Rest of Europe
8.3 North America
8.3.1 U.S.
8.3.2 Canada
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 AstraZeneca PLC
9.2 Actiza Pharmaceutical Private Limited
9.3 Bayer AG.
9.4 Bristol-Meyers Squibb Company
9.5 Endo International plc
9.6 Fresenius SE & Co. KGaA
9.7 Fortress Biotech, Inc.
9.8 GSK plc
9.9 Hikma Pharmaceuticals PLC
9.10 Johnson & Johnson
9.11 Merck & Co., Inc.
9.12 Nantong Jinghua Pharmaceutical Co., Ltd
9.13 Novartis AG
9.14 LEO Pharma A/S
9.15 Pfizer Inc.
